Literature DB >> 12949987

A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma.

Hiroyuki Kato1, Tatsuya Miyazaki, Yasuyuki Fukai, Masanobu Nakajima, Makoto Sohda, Junko Takita, Norihiro Masuda, Minoru Fukuchi, Ryokuhei Manda, Hitoshi Ojima, Katsuhiko Tsukada, Takayuki Asao, Hiroyuki Kuwano.   

Abstract

BACKGROUND: Our aim was to determine whether minichromosome maintenance protein (MCM) 2 expression is useful in predicting tumor proliferation rates and outcome after therapy in patients undergoing surgery for esophageal squamous cell carcinoma (SCC). In addition, we evaluated whether the expression of this proliferation marker was correlated with that of another marker, Ki-67, in esophageal SCC.
METHODS: We examined immunohistochemical expression of MCM2 and Ki-67 in surgically resected tissues from 93 patients with esophageal SCC.
RESULTS: The mean nuclear labeling index of MCM2 was markedly higher in SCC than in normal epithelia (P < 0.0001). A comparison of MCM2 labeling index and clinicopathological characteristics in 93 patients with esophageal cancer revealed significant associations between MCM2 labeling index and tumor status (P < 0.05), lymph node status (P < 0.01), metastatic status (P < 0.01), pathologic stage (P < 0.01), histologic grade (P < 0.05), and poor prognosis (P < 0.05). A comparison of Ki-67 labeling index and clinicopathological characteristics revealed significant associations between Ki-67 labeling index and lymph node status (P < 0.01), metastatic status (P < 0.05), pathologic stage (P < 0.05), histologic grade (P < 0.05), and poor prognosis (P < 0.05). The relationship between MCM2 and Ki-67 labeling indices in the primary tumor showed a significant correlation (P < 0.05), but the MCM 2 labeling index was considerably higher.
CONCLUSIONS: MCM2 may be a more reliable and useful marker than Ki-67 in assessing the growth of normal and tumor cells and in evaluating tumor aggressiveness and prognostic value in patients with esophageal SCC. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12949987     DOI: 10.1002/jso.10287

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  22 in total

1.  Schwann cell dedifferentiation is independent of mitogenic signaling and uncoupled to proliferation: role of cAMP and JNK in the maintenance of the differentiated state.

Authors:  Paula V Monje; Jennifer Soto; Ketty Bacallao; Patrick M Wood
Journal:  J Biol Chem       Date:  2010-07-15       Impact factor: 5.157

2.  Determination of cell proliferation using Mcm2 antigen and evaluation of apoptosis and TGF-beta1 expression in GH-secreting or clinically nonfunctioning pituitary adenomas.

Authors:  Cristina Micheletto Dallago; Ligia Maria Barbosa-Coutinho; Nelson Pires Ferreira; Rosalva Meurer; Julia Fernanda Semmelmann Pereira-Lima; Miriam da Costa Oliveira
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

3.  Altered expression of TFF-1 and CES-2 in Barrett's Esophagus and associated adenocarcinomas.

Authors:  Charles A Fox; Lisa M Sapinoso; Hong Zhang; Wanghai Zhang; Howard L McLeod; Gina R Petroni; Tarun Mullick; Christopher A Moskaluk; Henry F Frierson; Garret M Hampton; Steven M Powell
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

Review 4.  Replication proteins and human disease.

Authors:  Andrew P Jackson; Ronald A Laskey; Nicholas Coleman
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-01-01       Impact factor: 10.005

5.  Axon contact-driven Schwann cell dedifferentiation.

Authors:  Jennifer Soto; Paula V Monje
Journal:  Glia       Date:  2017-02-24       Impact factor: 7.452

Review 6.  Cell cycle and no end.

Authors:  Mathewos Tessema; Ulrich Lehmann; Hans Kreipe
Journal:  Virchows Arch       Date:  2004-02-17       Impact factor: 4.064

7.  Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity.

Authors:  Constantinos Giaginis; Maria Georgiadou; Konstantina Dimakopoulou; Gerasimos Tsourouflis; Elisavet Gatzidou; Gregorios Kouraklis; Stamatios Theocharis
Journal:  Dig Dis Sci       Date:  2008-05-09       Impact factor: 3.199

8.  Minichromosome maintenance 2 (MCM2) immunoreactivity in stage III human gastric carcinoma: clinicopathological significance.

Authors:  Naruo Tokuyasu; Kohei Shomori; Keisuke Nishihara; Hiroki Kawaguchi; Shinji Fujioka; Kensaku Yamaga; Masahide Ikeguchi; Hisao Ito
Journal:  Gastric Cancer       Date:  2008-03-29       Impact factor: 7.370

9.  Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma.

Authors:  A Mohan; M Kandalam; H L Ramkumar; L Gopal; S Krishnakumar
Journal:  Br J Ophthalmol       Date:  2006-03-23       Impact factor: 4.638

10.  Novel molecular markers of malignancy in histologically normal and benign breast.

Authors:  Aejaz Nasir; Dung-Tsa Chen; Mike Gruidl; Evita B Henderson-Jackson; Chinnambally Venkataramu; Susan M McCarthy; Heyoung L McBride; Eleanor Harris; Nazanin Khakpour; Timothy J Yeatman
Journal:  Patholog Res Int       Date:  2011-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.